XML 49 R31.htm IDEA: XBRL DOCUMENT v3.23.1
Collaboration and License Agreements (Tables)
12 Months Ended
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Revenue by Collaboration Partners

The following table summarizes the revenue by collaboration partner:

 

 

 

Year Ended December 31,

 

 

 

2022

 

 

2021

 

 

 

(in thousands)

 

AbbVie

 

$

18,563

 

 

$

11,546

 

Amgen

 

 

4,967

 

 

 

8,488

 

Astellas

 

 

20,491

 

 

 

17,278

 

Bristol Myers Squibb

 

 

9,142

 

 

 

-

 

Total revenue

 

$

53,163

 

 

$

37,312

 

Summary of Contract Liabilities

The following table presents changes in the Company’s total contract liabilities for the years ended in December 31, 2022 and 2021 (in thousands):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at
12/31/2020

 

 

Additions

 

 

Revenue Recognized

 

 

Balance at
12/31/2021

 

 

 

(in thousands)

 

Contract liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

Deferred revenue

 

$

318,707

 

 

$

3,834

 

 

$

(37,781

)

 

$

284,760

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at
12/31/2021

 

 

Additions

 

 

Revenue Recognized

 

 

Balance at
12/31/2022

 

 

 

(in thousands)

 

Contract liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

Deferred revenue

 

$

284,760

 

 

$

69,555

 

 

$

(52,989

)

 

$

301,326